What podcasts say about Len Schleifer
Every statement, with the speaker, the exact quote and the moment it was said.
What Len Schleifer has said on podcasts
8 statements · 6 positive · 2 negative
Dupixent is approved for eight indications and leads seven markets.
“it's approved for eight different indications. And it's the leading drug in seven of those eight.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 25:23
Eylea HD appears to be the most durable anti-VEGF product.
“HD seems to be the most durable product in the field of anti-VEGF therapy for these blinding retinal diseases.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 26:20
Libtayo lowered recurrence risk by 68 percent in an adjuvant study.
“we showed a dramatic improvement, 68 percent lowering of the risk of this cancer coming back.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 27:46
AI will not independently invent drugs.
“AI isn't going to invent the drugs.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 28:19
AI can identify medical-record associations more efficiently than humans.
“AI can go through that and find associations much more efficiently than you or I can.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 28:32
Acquiring external drug assets generally produces inadequate returns.
“when you look at the data. The return on the investment is just not there.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 30:12
Praluent can lower LDL cholesterol by 50 to 60 percent.
“Our drug, Prowlent, can lower it by 50% or 60%.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 31:19
Combining obesity drugs with Praluent could be highly complementary.
“I think it's a perfect marriage of two great opportunities.”
Open the episode · Mad Money w/ Jim Cramer 1/13/26Listen at 31:42
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.